Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

被引：0
|
作者：
Bernhard C. Pestalozzi
Christoph Tausch
Konstantin J. Dedes
Christoph Rochlitz
Stefan Zimmermann
Roger von Moos
Ralph Winterhalder
Thomas Ruhstaller
Andreas Mueller
Katharina Buser
Markus Borner
Urban Novak
Catrina Uhlmann Nussbaum
Bettina Seifert
Martin Bigler
Vincent Bize
Simona Berardi Vilei
Christoph Rageth
Stefan Aebi
机构：
[1] Universitaetsspital Zuerich,
[2] Brustzentrum Zuerich,undefined
[3] Universitaetsspital Basel,undefined
[4] Hôpital Cantonal Fribourg,undefined
[5] Kantonsspital Graubuenden Chur,undefined
[6] Luzerner Kantonsspital,undefined
[7] Breast Center St. Gallen,undefined
[8] Kantonsspital Winterthur,undefined
[9] Engeriedspital Bern,undefined
[10] Spitalzentrum Biel,undefined
[11] Inselspital Bern,undefined
[12] Kantonsspital Olten,undefined
[13] Kantonsspital Baselland,undefined
[14] SAKK Coordinating Center,undefined
来源：
BMC Cancer | / 17卷
关键词：
ER-positive early breast cancer; Adjuvant treatment recommendation; Multigene expression profiling; Recurrence score; Oncotype DX;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
    Pestalozzi, Bernhard C.
    Tausch, Christoph
    Dedes, Konstantin J.
    Rochlitz, Christoph
    Zimmermann, Stefan
    von Moos, Roger
    Winterhalder, Ralph
    Ruhstaller, Thomas
    Mueller, Andreas
    Buser, Katharina
    Borner, Markus
    Novak, Urban
    Nussbaum, Catrina Uhlmann
    Seifert, Bettina
    Bigler, Martin
    Bize, Vincent
    Vilei, Simona Berardi
    Rageth, Christoph
    Aebi, Stefan
    BMC CANCER, 2017, 17
  • [2] Adjuvant treatment recommendations for ER plus early breast cancer patients by Swiss tumor boards (SAKK 26/10)
    Pestalozzi, B. C.
    Tausch, C.
    Dedes, K. J.
    Rochlitz, C.
    Zimmermann, S.
    Von Moos, R.
    Winterhalder, R. C.
    Ruhstaller, T.
    Mueller, A.
    Buser, K. S.
    Borner, M. M.
    Novak, U.
    Nussbaum, C. Uhlmann
    Seifert, B.
    Bigler, M.
    Bize, V.
    Vilei, S. Berardi
    Rageth, C.
    Aebi, S. P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S313 - S313
  • [3] Comparisons of tumor-infiltrating lymphocytes and 21-gene recurrence score in ER-positive/ HER2-negative breast cancer
    Ahn, S. G.
    Cha, Y. J.
    Yoon, C.
    Bae, S. J.
    Kim, J.
    Jeong, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
    Ahn, Sung Gwe
    Cha, Yoon Jin
    Bae, Soon June
    Yoon, Chanik
    Lee, Hak Woo
    Jeong, Joon
    BMC CANCER, 2018, 18
  • [5] Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
    Sung Gwe Ahn
    Yoon Jin Cha
    Soon June Bae
    Chanik Yoon
    Hak Woo Lee
    Joon Jeong
    BMC Cancer, 18
  • [6] Chemosensitivity of ER-positive/HER2-negative breast cancers with higher 21-gene recurrence score (≥ 26): a study based on in vitro chemoresponse assay
    Ahn, S. G.
    Lee, H. W.
    Lim, J. W.
    Baek, S. H.
    Bae, S. J.
    Yoon, C.
    Cha, Y. J.
    Jeong, J.
    BREAST, 2017, 32 : S88 - S88
  • [7] 21-gene recurrence score assay as a predictor of pathological response in neoadjuvant chemotherapy administration for ER-positive/HER2-negative early-stage breast cancer.
    Morales Murillo, Serafin
    Gasol Cudos, Ariadna
    Rodriguez, Alvaro
    Canosa Morales, Carles
    Mele Olive, Jordi
    Vilardell, Felip
    Sanchez Guzman, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer
    Jung, Wonguen
    Kim, Kyubo
    Moon, Byung-In
    BREAST CARE, 2022, 17 (06) : 561 - 566
  • [9] Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
    Poorvu, Philip D.
    Gelber, Shari, I
    Rosenberg, Shoshana M.
    Ruddy, Kathryn J.
    Tamimi, Rulla M.
    Collins, Laura C.
    Peppercorn, Jeffrey
    Schapira, Lidia
    Borges, Virginia F.
    Come, Steven E.
    Warner, Ellen
    Jakubowski, Debbie M.
    Russell, Christy
    Winer, Eric P.
    Partridge, Ann H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) : 725 - +
  • [10] Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay
    Ahn, Sung Gwe
    Bae, Soong June
    Yoon, Changik
    Cha, Yoon Jin
    Lee, Hak Woo
    Lee, Seung Ah
    Jeong, Joon
    PLOS ONE, 2017, 12 (11):
12345